SEPN — Septerna Inc stock price, charts and financials

Latest market price

38.85

+0.02+0.05%

Overview Short InterestFilings

SEPNQT81Septerna Inc·NASDAQ

Overview Short InterestFilings

38.85+0.05%

Loading chart...

Signal & projected range

Insider open-market saleHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

AUPH-2.52%$15.45 MESO+4.64%$16.68 ZBIO-1.48%$31.95 GHRS-2.44%$29.53 TSHA-2.90%$6.37 STOK-1.47%$32.23 ABCL+34.78%$9.34 VRDN-2.25%$23.06

Snapshot

Index	-	P/E	-	EPS (ttm)	-	Insider Own	39.87%	Shs Outstand	45.08M	Perf Week	12.71%

Market Cap	1.75B	Forward P/E	-	EPS next Y	-2.39	Insider Trans	-0.72%	Shs Float	18.88M	Perf Month	2.62%

Enterprise Value	1.70B	PEG	-	EPS next Q	-	Inst Own	-	Short Float	7.43%	Perf Quarter	61.93%

Income	-36.23M	P/S	24.22	EPS this Y	-	Inst Trans	-	Short Ratio	7.84	Perf Half Y	58.88%

Sales	72.25M	P/B	4.59	EPS next Y	-45.36%	ROA	-6.33%	Short Interest	3.35M	Perf YTD	39.28%

Book/sh	-	P/C	16.11	EPS next 5Y	-	ROE	-9.44%	52W High	40.67 -4.48%	Perf Year	230.47%

Cash/sh	-	P/FCF	16.37	EPS past 3/5Y	-	ROIC	-11.28%	52W Low	10.63 265.63%	Perf 3Y	-

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	99.42%	Volatility	6.33% 6.56%	Perf 5Y	-

Dividend TTM	-	EV/Sales	23.55	EPS Y/Y TTM	44.04%	Oper. Margin	-77.07%	ATR (14)	2.30	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	4.71	Sales Y/Y TTM	-	Profit Margin	-49.88%	RSI (14)	63.00	Recom	1.88

Dividend Gr. 3/5Y	-	Current Ratio	4.71	EPS Q/Q	61.22%	SMA20	11.52%	Beta	1.09	Target Price	50.25

Payout	0.00%	Debt/Eq	0.06	Sales Q/Q	-	SMA50	13.45%	Rel Volume	0.69	Prev Close	38.83

Employees	130	LT Debt/Eq	0.06	Earnings	Aug 10	SMA200	40.50%	Avg Volume	397.26K	Price	38.85

IPO Date	Oct 25, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	54.40% 56.25%	Net Debt/EBITDA	0.93	Volume	274,144	Change	0.05%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-01-26	Reiterated	Truist Securities	Buy	$34 → $43
Jul-01-26	Reiterated	Guggenheim	Buy	$52 → $45
Jun-11-26	Initiated	Guggenheim	Buy	$52
Jun-08-26	Reiterated	Raymond James	Strong Buy	$38 → $53
Mar-10-26	Reiterated	Cantor Fitzgerald	Overweight	$60
Jan-20-26	Reiterated	HC Wainwright & Co.	Buy	$35
Dec-19-25	Initiated	Raymond James	Strong Buy	$38
Dec-15-25	Initiated	Truist	Buy	$34
Nov-14-25	Upgrade	Wells Fargo	Equal Weight → Overweight	$18 → $28
May-16-25	Reiterated	Wells Fargo	Equal Weight	$11 → $18

Latest News

Jul-07-26

Jul-07-2610:00AM

DigitalOcean, Agios Pharmaceuticals, Kingsoft Cloud And Other Big Stocks Moving Higher On TuesdayBenzinga

Jul-05-26

Jul-05-2609:35AM

Septerna's Chief People Officer Sold Nearly 12,000 Company Shares. What Does That Mean for Investors?fool.com

Jun-29-26

Jun-29-2611:05PM

Is Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares?fool.com

Jun-17-26

Jun-17-2602:18AM

Septerna: A De-Risking GPCR Story With Near-Term Upside CatalystsSeekingAlpha

Company

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023
Total Revenue	46	1	0
Cost of Goods Sold Incl. D&A	0	0	0
Gross Profit	46	1	0
Selling, General and Administrative Excl. Other	29	17	10
Research and Development	98	65	36
Other Operating Expense	0	0	-48
Operating Income	-81	-81	2
Interest Expense	0	0	0
Unusual Expense	—	—	—
Non-Operating Income (Expense)	32	9	3
Net Income Before Taxes	-49	-72	5
Income Taxes	0	0	1
Consolidated Net Income	-49	-72	4
Net Income From Continuing Operations	-49	-72	4
Net Income	-49	-72	4
EPS (Recurring)	-1.10	-1.93	0.03
EPS (Basic, Before Extraordinaries)	-1.10	-1.93	0.03
EPS (Diluted)	-1.10	-1.93	0.03
EBITDA	-47	-71	-45
Other After Tax Adjustments	—	—	—
Stock Option Compensation Expense	—	—	—
Price To Earnings Ratio	—	—	—
Price To Sales Ratio	26.67	847.30	—
Gross Margin	100.00	100.00	—
Operating Margin	-176.09	-8,100.00	—
Net Margin	-106.52	-7,200.00	—
Shares Outstanding	44	37	19
Market Capitalization	1,227	847	—
Operating Lease Expense	—	—	—

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Long Daniel D.	SVP, Drug Discovery	Aug 03 '26	Sale	34.47	3,334	114,920	96,412	Aug 05
Long Daniel D.	SVP, Drug Discovery	Aug 03 '26	Option Exercise	2.76	3,334	9,202	99,746	Aug 05
Bhatt Elizabeth	President and COO	Jul 15 '26	Option Exercise	6.81	4,000	27,240	178,209	Jul 17
Bhatt Elizabeth	President and COO	Jul 15 '26	Sale	33.99	4,000	135,974	174,209	Jul 17
Long Daniel D.	SVP, Drug Discovery	Jul 01 '26	Sale	34.36	3,333	114,528	96,412	Jul 02
Long Daniel D.	SVP, Drug Discovery	Jul 01 '26	Option Exercise	2.76	3,333	9,199	99,745	Jul 02
Shaikhly Samira	Chief People Officer	Jun 29 '26	Option Exercise	6.81	2,178	14,832	2,971	Jun 30
Shaikhly Samira	Chief People Officer	Jun 29 '26	Sale	35.18	2,178	76,622	793	Jun 30
Long Daniel D.	SVP, Drug Discovery	Jun 22 '26	Sale	35.51	15,000	532,582	96,412	Jun 24
Long Daniel D.	SVP, Drug Discovery	Jun 22 '26	Option Exercise	5.42	15,000	81,371	111,412	Jun 24
Shaikhly Samira	Chief People Officer	Jun 12 '26	Option Exercise	11.70	6,250	73,125	7,043	Jun 16
Shaikhly Samira	Chief People Officer	Jun 12 '26	Sale	35.08	6,250	219,224	793	Jun 16
Shaikhly Samira	Chief People Officer	Jun 01 '26	Option Exercise	1.87	5,935	11,111	6,728	Jun 03
Shaikhly Samira	Chief People Officer	Jun 01 '26	Sale	28.93	5,935	171,682	793	Jun 03
Shaikhly Samira	Chief People Officer	May 26 '26	Option Exercise	6.81	11,798	80,344	12,591	May 28

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.